Clinical Trial Highlights

• TAK-875 Reduces HbA1C in Patients with T2DM
• No Increased CV Events with DPP-4 Inhibitors
• EndoBarrier® Rapidly Improves Diabetes Parameters
• NAFLD: CV Risk Regardless of Hyperglycemia or Obesity
• Efficacy and Safety of Once-Weekly Exenatide versus Daily Liraglutide in Subjects with T2DM (DURATION-6)
• Efficacy of a Bihormonal Closed-Loop System to Control Postprandial and Post Exercise Glucose Excursions
• Combined Intensive BP and Glycemic Control Has No Benefit in Reducing CV Risk in Patients with T2DM
• Triple Therapy with Liraglutide + Metformin + Insulin Detemir Improves Glycemic Control with No Weight Gain and Low Rates of Hypoglycemia
• Daily Insulin Dose at One Year Predicts Weight Gain in People with Type 2 Diabetes Newly Treated with Insulin
• Liraglutide Reduces Insulin Dose without Affecting Glycemic Control in T1DM